Based on the patient’s blood tumor marker test results, ACTL-targeted cellular immunotherapy with dual-target antigens of CEA and CK-19 (complete protein precursor of CYFRA21-1) was initiated. The gene discussed is CEACAM5; the disease is neoplasm.